【摘要】 目的探讨乳果糖联合培菲康预防肝硬化自发性细菌性腹膜炎(SBP)的疗效。方法选择肝硬化失代偿期患者186例,随机分为乳果糖与培菲康联合治疗组和常规抗生素治疗组各93例,住院期间同时予以护肝利尿及对症支持治疗,用药3个月进行观察,并采集腹水样本,采用ELISA方法进行TNF-α和IL-6的检测。结果肝硬化患者应用乳果糖与培菲康联合治疗组SBP发生率为12.9%,而常规抗生素治疗组SBP发生率为21.5%,二者间比较差异有统计学意义(P<0.05)。SBP发生患者腹水TNF-α的水平为(1650±126)pg/mL,而未发生SBP为(1312±289)pg/mL,两组间比较差异有统计学意义(P<0.05)。SBP发生患者腹水IL-6的水平为(2566±138)pg/mL,而未发生SBP患者中为(924±251)pg/mL,两组间比较差异有统计学意义(P<0.01)。结论肝硬化患者应用乳果糖联合培菲康可显著降低SBP的发生率。腹水TNF-α和IL-6的水平可监测肝硬化患者SBP的发生。更多还原

【Abstract】 Objective To explore the clinical effect of combination of lactulose and Bifid-triple viable capsule on spontaneous bacterial peritonitis(SBP) with hepatic cirrhosis.Methods 186 cases of decompensated hepatic cirrhosis were randomly divided into lactulose and Bifid-triple viable capsule combination group(n = 93) and conventional antibiotic treatment group(n = 93).During hospitalization,all patients were treated with diuretics and supportive treatment.The clinical effect was observed after three months.In addition,the ascites was collected for TNF-α and IL-6 detection using ELISA.Results The incidence of SBP in lactulose and Bifid-triple viable capsule combination group was 12.9%,while that in conventional antibiotic therapy group reached to 21.5%,which showed significant difference(P < 0.05).The concentration of TNF-α was(1650 ± 126) pg / mL in ascites with SBP while(1312 ± 289) pg / mL in ascites without SBP,with a significant difference(P < 0.05).The concentration of IL-6 was(2566 ± 138) pg / mL in ascites with SBP while(924 ±251) pg/mL in ascites without SBP,with a significant difference(P < 0.05).Conclusion The combination of lactulose and Bifid-triple viable capsule could reduce the incidence of SBP significantly.The levels of TNF-α and IL-6 in ascites could be used to monitor the occurrence of SBP in patients with cirrhosis.更多还原